Publications by authors named "F Micoli"

is the leading bacterial cause of diarrhea worldwide, with increasing levels of antibiotic resistance. The greatest burden is among children aged <5 years in low- and middle-income countries, and efforts are ongoing to develop vaccines against this pathogen. One of the challenges associated with the development of a vaccine against is the need for a multivalent vaccine covering the most prevalent serotypes.

View Article and Find Full Text PDF

Background/objectives: Typhoid and paratyphoid fever together are responsible for millions of cases and thousands of deaths per year, most of which occur in children in South and Southeast Asia. While typhoid conjugate vaccines (TCVs) are licensed, no vaccines are currently available against Paratyphi A. Here we describe the design of a Paratyphi A conjugate.

View Article and Find Full Text PDF

Alum is the most used vaccine adjuvant, due to its safety, low cost and adjuvanticity to various antigens. However, the mechanism of action of alum is complex and not yet fully understood, and the immune responses elicited can be weak and antigen-dependent. While several antigens rapidly desorb from alum upon exposure to serum, phosphorylated proteins remain tightly bound through a ligand-exchange reaction with surface hydroxyls on alum.

View Article and Find Full Text PDF
Article Synopsis
  • Shigellosis is a serious health issue, especially for children under 5 in low- and middle-income countries, and is linked to growth problems and antibiotic resistance.
  • There is an urgent need for a broad-spectrum vaccine, with current research focusing on the role of anti-O-Antigen-specific IgG and verifying its functionality using a new high-throughput luminescence-based Serum Bactericidal Assay (L-SBA).
  • This study successfully refined the L-SBA to assess multiple Shigella serotypes, confirming its effectiveness and precision, which can help in understanding natural immune responses and testing vaccine efficacy.
View Article and Find Full Text PDF

Glycoconjugation is a well-established technology for vaccine development: linkage of the polysaccharide (PS) antigen to an appropriate carrier protein overcomes the limitations of PS T-independent antigens, making them effective in infants and providing immunological memory. Glycoconjugate vaccines have been successful in reducing the burden of different diseases globally. However, many pathogens still require a vaccine, and many of them display a variety of glycans on their surface that have been proposed as key antigens for the development of high-valency glycoconjugate vaccines.

View Article and Find Full Text PDF